cbdMD Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways

Core Viewpoint - cbdMD, Inc. is launching a strategic initiative to enhance its regulatory science, safety, and intellectual property assets, aiming to create a comprehensive cannabinoid compliance platform aligned with federal healthcare evaluation frameworks [1][7]. Group 1: Acquisition and Integration - cbdMD acquired substantially all assets of Bluebird Botanicals, which is expected to contribute an estimated 10% to revenue growth and includes a self-affirmed GRAS determination for a full-spectrum hemp extract [3][4]. - The integration of Bluebird's scientific and regulatory assets with cbdMD's existing clinical and toxicology foundation aims to create one of the most comprehensive safety and regulatory dossiers for cannabinoid formulations [2][4]. Group 2: Regulatory Science Program - An integrated GRAS and regulatory science program is being launched to consolidate and modernize cbdMD's science portfolio, primarily executed through its internal scientific and regulatory organization [5]. - Key objectives of the program include preparing a new self-affirmed GRAS determination for cbdMD's broad-spectrum formulations and strengthening Bluebird's existing full-spectrum GRAS dossier [6]. Group 3: Strategic Vision - The CEO of cbdMD emphasized the importance of building a durable regulatory-grade foundation to engage effectively with regulators and healthcare stakeholders as federal regulations evolve [7].